GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (STU:PH4) » Definitions » Research & Development

CStone Pharmaceuticals (STU:PH4) Research & Development : €71.13 Mil (TTM As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. CStone Pharmaceuticals's Research & Development for the six months ended in Jun. 2023 was €24.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was €71.13 Mil.

CStone Pharmaceuticals Research & Development Historical Data

The historical data trend for CStone Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Research & Development Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 179.09 176.57 181.32 83.16 67.78

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.07 37.67 47.06 24.07 -

CStone Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €71.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals  (STU:PH4) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CStone Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (STU:PH4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (STU:PH4) » Definitions » Research & Development
Comparable Companies
HKSE:01244 HKSE:01873 HKSE:01167 HKSE:06622 HKSE:02496 HKSE:06978 HKSE:01672 HKSE:02181 HKSE:02256 HKSE:02137 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CSPHF:USA 02616:Hong Kong
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
Website
https://www.cstonepharma.com
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (STU:PH4) Headlines

No Headlines